Amarantus BioScience Holdings, Inc.
AMBSOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$36841
P/E Ratio—
52W High$0.0003
52W Low$0.00001
Amarantus BioScience Holdings, Inc. (AMBS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMBS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.10M | $0.00M | $0.07M | $20.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.10M | $0.00M | $0.07M | $20.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | — | 100.00% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $0.36M | $0.15M | $0.70M | $1.67M | $3.04M |
| Operating Income | ($0.27M) | ($0.15M) | ($0.63M) | $18.33M | ($3.04M) |
| Operating Margin %(computed) | -281.13% | — | -840.70% | 91.64% | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($4.76M) | ($10.20M) | ($0.63M) | $18.38M | ($10.58M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | ($0.00M) |
| Net Income | ($4.76M) | ($10.20M) | ($0.63M) | $18.38M | ($10.58M) |
| Net Margin %(computed) | — | — | -840.70% | 91.88% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-0.02 | $-0.00 | $0.07 | $-0.05 |
| Wtd Avg Shares | 579.61M | 465.11M | 368.41M | 269.92M | 234.16M |
| EBITDA | ($4.53M) | ($9.96M) | ($0.42M) | $18.55M | ($3.04M) |
| EBITDA Margin %(computed) | — | — | -564.53% | 92.74% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Amarantus BioScience Holdings, Inc. data
About Amarantus BioScience Holdings, Inc. (AMBS) Income Statement
Amarantus BioScience Holdings, Inc. (AMBS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, AMBS reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -4995.23%.
Frequently asked questions
AMBS · 4 questionsAmarantus BioScience Holdings, Inc. (AMBS) reported revenue of $0.00B for 2022, up —% year-over-year.
AMBS revenueAMBS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09